Citation Impact
Citing Papers
Identification of a Primary Target of Thalidomide Teratogenicity
2010 StandoutScience
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
2008
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
2013
Reporting methods in studies developing prognostic models in cancer: a review
2010
The DNA-damage response in human biology and disease
2009 StandoutNature
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
2001
Foscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study
1998
Southwestern Internal Medicine Conference: Clinical Use of Hematopoietic Growth Factors
1993
Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
2011 Standout
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
2012
Clinical translation of angiogenesis inhibitors
2002 Standout
Cancer to bone: a fatal attraction
2011 Standout
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
2009 Standout
Telomere dysfunction in ageing and age-related diseases
2022
A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced‐dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients
2002
Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells
1999 Standout
Can Only Partial T-Cell Depletion of the Graft before Hematopoietic Stem Cell Transplantation Mitigate Graft-versus-Host Disease While Preserving a Graft-versus-Leukemia Reaction? A Prospective Phase II Study
2006
Hallmarks of aging: An expanding universe
2023 Standout
Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease
2006
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
2003
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Body mass index and risk of multiple myeloma: A meta‐analysis
2007
Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma
2007
Multiple Myeloma
2004
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis
2017
Multiple myeloma
2000 Standout
Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial
2002 Standout
Personalized Dosing of Cyclophosphamide in the Total Body Irradiation–Cyclophosphamide Conditioning Regimen: A Phase II Trial in Patients With Hematologic Malignancy
2009
Neutrophil-Regulatory Tn Lymphocytes
2006
Nitric Oxide and Peroxynitrite in Health and Disease
2007 Standout
Chronic myelogenous leukemia: A review
1996
Insulin and insulin-like growth factor signalling in neoplasia
2008 Standout
How stem cells age and why this makes us grow old
2007
The DNA Damage Response: Making It Safe to Play with Knives
2010 Standout
Myeloma Responses and Tolerance Following Combined Kidney and Nonmyeloablative Marrow Transplantation: In Vivo and In Vitro Analyses
2006
Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
2006
Graft-versus-host disease
2009 Standout
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA
2005
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
2010 Standout
OPTIONS FOR THERAPY IN CHRONIC MYELOID LEUKAEMIA
1995
Prevention of Venous Thromboembolism
2004 Standout
Sickle-cell disease
2010 Standout
The Biological Functions of T Helper 17 Cell Effector Cytokines in Inflammation
2008 Standout
A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment
2013
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study
2008 Standout
Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells
2007
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
2001 Standout
Thalidomide in multiple myeloma: lack of response of soft‐tissue plasmacytomas
2001
Neutrophils, from Marrow to Microbes
2010 Standout
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies
2008 Standout
Thalidomide
2004
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers
2004
Drug Insight: thalidomide as a treatment for multiple myeloma
2005
Reporting performance of prognostic models in cancer: a review
2010
Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer
2012 StandoutNobel
The Hallmarks of Aging
2013 Standout
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
2014 Standout
High-Dose Treatment With Autologous Stem Cell Transplantation in Multiple Myeloma: Past, Present, and Future
2007
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
HLA-Mismatched Renal Transplantation without Maintenance Immunosuppression
2008 Standout
Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers
2001
Neutrophil recruitment and function in health and inflammation
2013 Standout
Unrelated donor bone marrow transplantation using a chemotherapy‐only preparative regimen for adults with high‐risk acute myelogenous leukemia
2006
Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer
2008
Chimeric antigen receptor T-cell therapies for lymphoma
2017
Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma
2002
Leukocyte Depleted, Unscreened Blood Products Give a Low Risk for CMV Infection and Disease in CMV Seronegative Allogeneic Stem Cell Transplant Recipients with Seronegative Stem Cell Donors
2002
Cellular senescence: from physiology to pathology
2014 Standout
Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation
2009 Standout
Polyclonal anti‐T‐cell globulin as part of the preparative regimen for pediatric allogeneic stem‐cell transplantation
2001
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
Nonmyeloablative HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Phenotype
2014
Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation.
2001
Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity
2002
Glucocorticoids Inhibit Bioactive IL-12p70 Production by In Vitro-Generated Human Dendritic Cells Without Affecting Their T Cell Stimulatory Potential
1998
Recent major improvement in long-term survival of younger patients with multiple myeloma
2007
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Current concepts in the diagnosis and management of cytokine release syndrome
2014 Standout
Apoptosis in the Pathogenesis and Treatment of Disease
1995 StandoutScience
Intravenous Immunoglobulin: Striving for Appropriate Use
2006
Anti-Inflammatory Mechanisms in the Vascular Wall
2001
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
2001
Multiple Sclerosis
2018 Standout
Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma
2008
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
Low-dose of thalidomide in the treatment of refractory myeloma.
2000
Corticosteroids can reverse severe imatinib-induced hepatotoxicity.
2006
VENO-OCCLUSIVE DISEASE OF THE LIVER
1955
Graft-versus-leukemia effects of transplantation and donor lymphocytes
2008
Improved survival in multiple myeloma and the impact of novel therapies
2007 Standout
Thalidomide in multiple myeloma
2005
Chimeric Antigen Receptor Therapy
2018 Standout
Interleukin-10 and the Interleukin-10 Receptor
2001 Standout
Descriptive and Prognostic Value of Patient-Reported Outcomes: The Bortezomib Experience in Relapsed and Refractory Multiple Myeloma
2006
Dauer larva quiescence alters the circuitry of microRNA pathways regulating cell fate progression inC. elegans
2012 StandoutNobel
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Health-Related Quality of Life in Younger Patients With Chronic Lymphocytic Leukemia Treated With Fludarabine Plus Cyclophosphamide or Fludarabine Alone for First-Line Therapy: A Study by the German CLL Study Group
2007
Metal–Organic Frameworks in Biomedicine
2011 Standout
Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation
2002
Multiple Myeloma
2011 Standout
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
2006
Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003
2007
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement
2015 Standout
The World Health Organization (WHO) classification of the myeloid neoplasms
2002 Standout
Risk assessment in haematopoietic stem cell transplantation: Conditioning
2007
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
2002 Standout
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
2015 Standout
Works of Stig Lenhoff being referenced
Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
2000
Impact of age on survival after intensive therapy for multiple myeloma: a population‐based study by the Nordic Myeloma Study Group
2006
Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the chronic leukemia working party of the EBMT
2009
Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe
2006
CYTOKINE REGULATION OF GM-CSF AND G-CSF SECRETION BY HUMAN UMBILICAL CORD VEIN ENDOTHELIAL CELLS (HUVEC)
1996
Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation
2005
Health-Related Quality of Life in Multiple Myeloma Patients Receiving High-Dose Chemotherapy with Autologous Blood Stem-Cell Support
2001
Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT
2012
Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000–2011
2017
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience
2014
Effects of immunosuppressive drugs and antibiotics on GM‐CSF and G‐CSF secretion in vitro by monocytes, T lymphocytes and endothelial cells
1996
No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients
1997
Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.
2004
Increased Risk of Chronic Graft-Versus-Host Disease, Obstructive Bronchiolitis, and Alopecia With Busulfan Versus Total Body Irradiation: Long-Term Results of a Randomized Trial in Allogeneic Marrow Recipients With Leukemia
1999
Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes
2005
Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation.
2006
A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group
1994
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) in serum in bone marrow transplanted patients.
1991
Impact of Age on Survival after Intensive Therapy in Newly Diagnosed Multiple Myeloma. The Nordic Myeloma Study Group (NMSG).
2004
Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group.
2000
Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor
2002